drugset / Trial / NCT07722611

A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)

NCT07722611 ↗

Phase 2/3 Recruiting 380 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

Researchers are looking for new ways to treat polycythemia vera (PV). People with PV may receive treatment to lower the number of red blood cells in the blood, but the usual treatments may not work for everyone. Researchers want to learn if a trial medicine called bomedemstat, also called MK-3543, can treat PV. In this study, researchers will compare bomedemstat to 2 usual treatments for PV. The goal of this study is to learn if more participants who take bomedemstat reach healthy blood cell counts and avoid major health problems from PV, compared to those who receive a usual treatment.

Timeline

Start
2026-10-07
Primary completion
2032-06-25
Completion
2032-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Bomedemstat Small molecule — Oral
Comparator Ropeginterferon alfa-2b Protein / enzyme biologic — Subcutaneous
Comparator Ruxolitinib Small molecule — Oral